Ampicillin Gram-Negative Coverage
Ampicillin has limited gram-negative coverage, primarily effective against E. coli, Proteus mirabilis, H. influenzae, and some Salmonella/Shigella species, but resistance rates are high (40-60% for E. coli) and it lacks activity against Pseudomonas, Klebsiella, and most other Enterobacteriaceae.
Covered Gram-Negative Organisms
According to FDA labeling and clinical guidelines, ampicillin demonstrates activity against 1:
Reliably Covered:
- Haemophilus influenzae (respiratory infections)
- Proteus mirabilis (urinary tract infections, septicemia)
- Neisseria meningitidis (meningitis)
- Neisseria gonorrhoeae
Variable Coverage (High Resistance Rates):
- Escherichia coli - Only 40-60% remain susceptible 2, 3
- Salmonella species (including S. typhi)
- Shigella species
NOT Covered:
- Pseudomonas aeruginosa - inherently resistant 1
- Klebsiella species - generally insensitive 4
- Enterobacter species - generally insensitive 4
- Acinetobacter baumannii - requires sulbactam component 5
Critical Resistance Considerations
The major limitation is beta-lactamase production. Ampicillin does NOT resist destruction by penicillinase 1. Historical data shows 80% E. coli susceptibility in 1967 4, but current resistance reaches 40-60% 2. Recent 2024 data confirms ampicillin/amoxicillin shows >55% resistance across all age groups for UTIs 3.
Clinical Dosing Recommendations
Adults 1:
- Standard dose: 1-2 g IV every 4-6 hours
- High-dose for enterococcal coverage: 18-30 g IV daily in divided doses 6
- Meningitis: Higher doses required for CNS penetration
Pediatrics 7:
- General infections: 50 mg/kg IV every 6 hours (QDS)
- Meningitis: 50 mg/kg IV every 6 hours for 3 weeks
- Sepsis (with gentamicin): 50 mg/kg IV every 6 hours
When to Use Ampicillin vs. Alternatives
Use ampicillin alone ONLY when:
- Treating enterococcal infections (remains preferred anti-enterococcal agent) 2
- Documented susceptibility confirmed by culture
- Treating uncomplicated VRE cystitis (high-dose regimen) 6
Ampicillin-sulbactam is superior for:
- Mixed aerobic/anaerobic infections 8, 9
- Animal/human bite wounds 9, 10
- Intra-abdominal infections 11
- Carbapenem-resistant Acinetobacter (sulbactam provides the activity) 5, 12
Better alternatives for empiric gram-negative coverage:
- Ceftriaxone/cefotaxime - broader gram-negative spectrum 13, 11
- Fluoroquinolones - better E. coli coverage but reserve for specific indications 9
- Piperacillin-tazobactam - broader coverage including Pseudomonas 11
- Amoxicillin-clavulanate - overcomes beta-lactamase resistance 9, 11
Common Pitfalls
Do not use ampicillin monotherapy for:
- Empiric treatment of hospital-acquired infections
- Suspected Pseudomonas or Klebsiella infections
- Community-acquired UTIs without culture confirmation (>55% resistance) 3
- Pneumonia in patients with COPD (H. influenzae may be resistant) 13
Always add aminoglycoside when treating:
The combination of ampicillin with gentamicin provides synergy and broader coverage, addressing ampicillin's gram-negative limitations while maintaining enterococcal activity 7, 11.